

Ref No: PSPPROJECT/SE/84/23-24

February 12, 2024

Corporate Relations Department
BSE Limited
Floor 25, P.J. Towers,
Dalal Street, Mumbai- 400 001
Scrip code: 540544

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051
Scrip Symbol: PSPPROJECT

Dear Sir/Madam,

Subject: Newspaper publication of Financials Results for Q3FY24

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copies of the newspaper advertisement of financial results of the Company for the quarter and Nine month ended December 31, 2023 published in the following newspapers on February 10, 2024:

1. Financial Express (National Daily English Newspaper)
2. Financial Express (Gujarati Edition- Newspaper in Regional Language)

Kindly take the above on your record.

Thanking You,

For PSP Projects Limited

Kenan Patel
Company Secretary & Compliance Officer

Encl.: As above



Aster DM Healthcare Limited

CIN : L85110KA2008PLC147259

Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India.
Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Amount in INR crores except per share data)

Particulars	Consolidated						Standalone					
	Quarter ended			Nine Months ended			Quarter ended			Nine Months ended		
	31-Dec-23 (Unaudited)	30-Sep-23 (Unaudited)	31-Dec-22 (Unaudited)	31-Dec-23 (Unaudited)	31-Dec-22 (Unaudited)	31-Mar-23 (Audited)	31-Dec-23 (Unaudited)	30-Sep-23 (Unaudited)	31-Dec-22 (Unaudited)	31-Dec-22 (Unaudited)	31-Mar-23 (Audited)	
Total Income	3,718.56	3,325.22	3,200.67	10,268.35	8,734.78	12,011.13	537.83	529.89	409.33	1,536.24	1,141.82	1,583.51
Net profit/(loss) before tax	233.46	(5.16)	173.44	301.55	329.30	535.08	53.19	56.89	41.44	162.70	128.28	182.33
Net profit/(loss) after tax	209.22	(15.33)	159.03	213.74	282.90	475.49	53.19	59.06	34.56	165.07	121.42	173.29
Total Comprehensive Income/(loss)	208.96	12.75	191.59	238.90	466.88	674.44	53.19	59.06	34.56	165.07	121.42	173.70
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52
Other Equity	-	-	-	-	-	3,948.55	-	-	-	-	-	2,831.04
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised
Basic	3.60	(0.62)	2.80	3.08	5.11	8.54	1.07	1.19	0.70	3.32	2.44	3.48
Diluted	3.60	(0.62)	2.80	3.08	5.10	8.53	1.07	1.19	0.69	3.31	2.44	3.48


*The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08, 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.

*The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.

*The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

For Aster DM Healthcare Limited
Sd/-
Alisha Moopen
Deputy Managing Director
DIN: 02432525

Place: Dubai
Date: February 08, 2024



Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481
Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com
CIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023

Sr. No.	Particulars	Rupees in Million					
		3 Months ended		Preceding 3 Months ended		Year to date figures for the current period	
		31/12/2023 (Unaudited)	30/09/2023 (Unaudited)	31/12/2022 (Unaudited)	30/09/2022 (Unaudited)	31/12/2023 (Unaudited)	31/12/2022 (Unaudited)
1	Total Income from operations	45,052	43,688	42,571	140,136	122,269	172,374
2	Net Profit for the period before exceptional items and tax	9,255	10,072	7,801	32,761	21,068	31,939
3	Net Profit for the period after exceptional items but before tax	9,255	10,072	7,801	32,619	21,039	25,897
4	Net Profit for the period from continuing operations	7,678	8,017	6,225	26,574	16,661	19,649
5	Profit/(Loss) after tax from discontinued operations	218	(10)	4	198	(24)	(46)
6	Net Profit for the period after tax and Non-Controlling Interest	7,896	8,007	6,229	26,772	16,637	19,603
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	8,099	7,446	5,479	26,476	13,444	16,459
8	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,012	1,012	1,012	1,012
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)	-	-	-	-	-	174,146
10	Earnings per share for continuing operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
b	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
b	Diluted (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30

Note:
[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

By Order of the Board,
For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Date: February 9, 2024
Place: Ahmedabad



National Commodity & Derivatives Exchange Limited

CIN : U51909MH2003PLC140116

Regd Office : Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West, Mumbai, Maharashtra 400078

Ph: 022-66406789 | Email: askus@ncdex.com | Website: www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

(Rs. In lakhs)

Sl. No.	Particulars	Standalone			Consolidated		
		Quarter ended	Quarter ended	Nine months ended	Quarter ended	Quarter ended	Nine months ended
		31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)
1.	Total Income from operations	1,210	1,167	4,133	3,313	3,430	10,209
2.	Net profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	(1,438)	(1,415)	(3,619)	(1,311)	(1,512)	(3,275)
3.	Net profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary items#)	1,268	(1,415)	(323)	(1,311)	(1,548)	(3,231)
4.	Net profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary items#)	1,488	(1,045)	321	(1,126)	(1,113)	(2,497)
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1,521	(1,065)	357	(1,107)	(1,164)	(2,505)
6.	Equity Share Capital	5,068	5,068	5,068	5,068	5,068	5,068
7.	Reserves (excluding Revaluation Reserve) as shown in Audited Balance Sheet of the previous year	-	-	-	-	-	-
8.	Earnings Per Share (FV ₹ 10 each) (for continuing and discontinued operations)						
1.	Basic (₹): Not annualised	2.94	(2.06)	0.63	(2.15)	(2.11)	(4.69)
2.	Diluted (₹): Not annualised	2.94	(2.06)	0.63	(2.15)	(2.11)	(4.69)

Notes:

1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com
2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.

3 # (i) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has received excess contribution of Rs. 15 lakh and Rs. 590 lakh during the half year ended September 30, 2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd. (NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31, 2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

(ii) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item.

(iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors
sd/-
Arun Raste
Managing Director & Chief Executive Officer
DIN - 08561128

Place: Mumbai
Date: February 9, 2024

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat
Phone No. : +91-79-68138700 || Fax : +91-79-68138725 || CIN : L24230GJ1984PLC007440
Email Id : complianceofficer@concordbiotech.com || Website : www.concordbiotech.com
Regd. Office & Plant : 1482-86, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India
Phone No. : +91-2714-222604, 398200 || Fax : +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

(Rs. In lakhs except per share data)

Sl. No.	Particulars	Standalone (Unaudited)		Consolidated (Unaudited)	
		Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022	Nine Months ended on 31/12/2022
1	Total Income from Operations	24,079.65	69,796.98	24,068.29	69,796.98
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items#)	10,008.37	27,827.50	10,624.99	28,384.44
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary Items#)	10,008.37	27,827.50	10,624.99	28,384.44
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary Items#)	7,455.30	20,751.75	7,907.55	21,308.69
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	1,28,151.88	-	1,28,151.88
8	Earnings Per Share (Face Value of Rs. 1/- each) (for continuing and discontinued operations - Not Annualised)				
1)	Basic	7.13	19.84	7.56	7.41
2)	Diluted	7.13	19.84	7.56	7.41

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com

(b) # - Exceptional and / or Extraordinary Items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.

(c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 08, 2024.

For and on behalf of board of directors of Concord Biotech Limited
Ankur Vaid
Joint Managing Director & CEO - DIN : 01857225
Date : February 8, 2024

PSP Projects Limited

CIN : L45201GJ2008PLC054868
Registered Office : PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058
Website : www.pspprojects.com

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

Sr. No.	Particular	Consolidated		
		Quarter Ended	Nine Months Ended	
		31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)
1.	Total Income from Operations	71,118.31	50,659.07	1,85,617.46
2.	Net Profit for the period (before Tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	4,204.40	4,824.99	14,468.84
3.	Net Profit for the period (after tax, Exceptional and Extraordinary Items before Share of Profit/(Loss) from Joint Venture)	3,106.66	3,532.82	10,737.75
4.	Net Profit for the period (after tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	3,108.32	3,536.01	10,745.06
5.	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	3,110.62	3,538.31	10,751.96
6.	Paid-up Equity Share Capital - Face Value ₹ 10/- each	3,600.00	3,600.00	3,600.00
7.	Other Equity excluding Revaluation Reserves	-	-	-
8.	Earnings Per Share of ₹ 10/- each (in ₹) (Not Annualised)			
a	Basic	8.63	9.82	29.85
b	Diluted	8.63	9.82	29.85

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024.

2. Additional information on Unaudited Standalone Financial Results are as follows:

Particular	Standalone		
	Quarter Ended	Nine Months Ended	
	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)
Revenue from Operations	69,661.92	49,739.28	1,81,332.80
Profit/(Loss) before tax and Exceptional item	4,397.86	4,815.39	14,636.12
Profit/(Loss) after tax and Exceptional item	3,251.85	3,529.50	10,864.77

3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com)

For and on behalf of Board of Directors of PSP Projects Limited
sd/-
Prahaldhbai S. Patel
Chairman, Managing Director & CEO
DIN: 00037637
Place : Ahmedabad
Date : February 9, 2024



CIN:U65929MH1990PLC057829
Regd. Office: AVINISHA TOWER, MEHADIA CHOWK, DHANTOLI, NAGPUR - 440 012. Ph no.0712-6663999
Website: www.berarfinance.com
E-mail: investor.relations@berarfinance.com

Extract of Financial Results for the quarter ended December 31, 2023 [Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)]

(₹ in Lakhs, except per equity share data and Debt Equity Ratio)

Sr. No.	PARTICULARS	Quarter ended	Quarter ended	Year ended
		Dec. 31, 2023	Dec. 31, 2022	March 31, 2023
		UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations	6662.90	6259.69	21788.93
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	517.58	892.62	1708.12
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	522.11	897.90	1709.27
6	Paid-up Equity Share Capital	1233.68	1233.68	1233.68
7	Reserves (excluding Revaluation Reserve)	11895.60	10345.60	11895.60
8	Securities Premium Account	14123.94	14123.94	14123.94
9	Net worth (Including Retained earnings and ESOP)	29113.77	27579.63	27523.6

